




EPICARDIO AWARDED INNOVATE UK R&D GRANT

Epicardio Ltd secures government funding to bring simulation-based Covid-19 Intensive Care training to medics struggling with influx of new patients




Funded by
Innovate UK

London UK based Medical Simulation company Epicardio has secured Innovate UK Government funding to accelerate development of an eTraining package to help medical staff understand and operate the new wave of ICU (Intensive Care Unit) mechanical ventilators delivered in response to the Covid-19 crisis.

With the potential for intense demand for ICU places, stretched staff are in desperate need of training to use new and unfamiliar ventilators, for which on-the-job learning is simply not possible. Epicardio's unique solution provides a virtual training App, accessible via laptop and iPad which permits interactive simulation of the patient, allowing medics to learn before doing. As well as ventilator training, the App teaches temporary cardiac pacing, another critical intervention in ICU patients with acute respiratory distress syndrome.



Epicardio CEO Vassilios Hurmusiadis explained “We are thrilled that Innovate UK has seen the potential of our business model. This will allow us to accelerate growth and fast-track our vision. Our current products focus on modelling the complexities of the human heart, so we jumped at the challenge to adapt our product to address the new challenges faced by the pandemic”.




NHS Cardiologist and team member Dr Malcolm Finlay adds “The Covid-19 pandemic has highlighted the advantages of remote learning. Epicardio's unique simulation tools provide unparalleled education opportunities for healthcare workers. As one of those drafted into the front-line of Covid-19 treatment I was able to observe the desperate need for training first hand. This product will help NHS staff save lives”.

As more young and inexperienced NHS staff are being fast tracked into ICU, the NHS needs fast and effective eTraining. Mechanical ventilation and temporary cardiac pacing are the two procedures with the most critical interventions in ICU patients with acute respiratory distress syndrome.

Innovate UK funding will enable Epicardio to realise its next step towards establishing itself as the global leader of simulation-based medical eTraining, improving access and reducing costs and patient risk.

Epicardio Ltd develops healthcare eTraining simulation apps that shorten the learning curve, improving access and reducing costs and patient risk. Our current product range is used by medical schools, hospitals and the cardiac devices industry. Epicardio Simulation™ is used globally by **BOSTON SCIENTIFIC EDUCARE**, Schiller AG, Abbott, Cleveland Clinic, Oxford Medical School, Barts Heart Centre, and many more. For more information please visit www.epicardio.com



Innovate UK drives productivity and economic growth by supporting businesses to develop and realise the potential of new ideas. We connect businesses to the partners, customers and investors that can help them turn ideas into commercially successful products and services and business growth. We fund business and research collaborations to accelerate innovation and drive business investment into R&D. Our support is available to businesses across all economic sectors, value chains and UK regions. Innovate UK is part of UK Research and Innovation. For more information visit innovateuk.ukri.org

LinkedIn

Twitter

Facebook

Copyright © 2020 Epicardio Ltd. All rights reserved.

UK Registration: 7585521. UK VAT: GB888190278. UK Registered Office: 18-20 Hill Rise, Richmond, London TW10 6UA, UK
USA Minnesota Registration: #1034269200025. USA MN Registered Office: 1010 Dale Street North, Saint Paul, MN 55117 USA
USA Florida Registration: #F17000004778. USA FL Registered Office: 1200 South Pine Island Road, Plantation, FL 33324 USA
USA FEIN: 98-1372593

Tel: +44(0)2089481080 Email: contact@epicardio.com Web: www.epicardio.com